Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

Open access
Fournier, Agnès, Berrino, Franco, Clavel-Chapelon, Françoise · 2007 · Breast Cancer Research and Treatment

Abstract

Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study. Invasive breast cancer cases were identified through biennial self-administered questionnaires completed from 1990 to 2002. During follow-up (mean duration 8.1 postmenopausal years), 2,354 cases of invasive breast cancer occurred among 80,377 postmenopausal women. Compared with HRT never-use, use of estrogen alone was associated with a significant 1.29-fold increased risk (95% confidence interval 1.02-1.65). The association of estrogen-progestagen combinations with breast cancer risk varied significantly according to the type of progestagen: the relative risk was 1.00 (0.83-1.22) for estrogen-progesterone, 1.16 (0.94-1.43) for estrogen-dydrogesterone, and 1.69 (1.50-1.91) for estrogen combined with other progestagens. This latter category involves progestins with different physiologic activities (androgenic, nonandrogenic, antiandrogenic), but their associations with breast cancer risk did not differ significantly from one another. This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous). These findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10549-007-9523-x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 694

Metadata

Authors
Fournier, A., Berrino, F., & Clavel-Chapelon, F.
Affiliations
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Venue
Breast Cancer Research and Treatment
Published
2007-02-27
Volume
107
Issue
1
Pages
103-111
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W2051559140
Cited by
693
References
28
Citations by year
2026: 32 · 2025: 33 · 2024: 27 · 2023: 30 · 2022: 37 · 2021: 41 · 2020: 91 · 2019: 43 · 2018: 32 · 2017: 22 · 2016: 24 · 2015: 26 · 2014: 28 · 2013: 41 · 2012: 34
FWCI
30.07
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords
hormone replacement therapy, breast cancer risk, estrogen alone, progestogens, dydrogesterone, progesterone, postmenopausal women, E3N cohort
MeSH terms
Adult, Aged, Breast Neoplasms, Dydrogesterone, Estrogens, Female, Humans, Middle Aged, Neoplasm Invasiveness, Progestins, Progesterone, Risk, Cohort Studies, Postmenopause, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. https://app.cochat.ai/papers/10.1007/s10549-007-9523-x
The paper
Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2007). Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-007-9523-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.